Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 InSea2 Impacts Glycemic Response - Nutraceuticals World

What are you searching for?

Sign in
Research

InSea2 Impacts Glycemic Response

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

In a recent randomized, crossover, double-blind, placebo-controlled human clinical trial led by the Institute of Nutraceuticals and Functional Foods of Laval University (Quebec, Canada), InSea2, from innoVactiv (at a single dose of 500 mg), induced a statistically significant 44% decrease in the normal glycemic response that follows ingestion of a standardized meal (white bread) in 23 healthy volunteers. InSea2 also induced a 22% reduction in initial insulin production and an overall 6% reduction in the area under the curve of the insulin response. Additionally, InSea2 improved insulin sensitivity by nearly 7% (Cederholm index) after a single use of the product. For further information: www.innovactiv.com

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters